Currently Viewing:
Evidence-Based Oncology February 2019
Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options
Mary Caffrey
Is Immunotherapy the Future of Glioblastoma Treatment?
Samantha DiGrande
Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma
Mary Caffrey
Moving Toward the "Tipping Point" for Transformation in Cancer Care
Mary Caffrey
Medical World News: Clinical Updates
Coverage by Jaime Rosenberg, Laura Joszt, Samantha DiGrande, and Kelly Davio
Medical World News: Regulatory Updates
Coverage by Jaime Rosenberg, Laura Joszt, Samantha DiGrande, and Kelly Davio
Currently Reading
AJMCtv® Interviews, February 2019

AJMCtv® Interviews, February 2019

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at
Mutational events can help to delineate minimal residual disease, as well. So, if you have a mutational profile at the time of diagnosis, you can use those identified molecular events at the time of remission to determine the depth of that remission. And you can make deci- sions, potentially, although not yet proven, you can at some point in the future, you might be able to make decisions about what therapy to give next, especially with respect to allogeneic transplant or intensification of therapy or capitalizing on some of these targeted therapeutics to drive deeper remissions and thereby get better long-term outcomes for patients.

I think these molecular profiles help us to think about patients. I think if you have a patient with 6 or 9 mutational events, that patient is overall less likely to do well than a patient who has less events. And Elli Papaemmanuil [assistant attending computational oncologist, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center] has shown that in her original paper in 2016 published in the New England Journal of Medicine.

I think that approach with casting a broader net and capturing the mutational events that characterize leukemia is likely to help us in the long-term manage patients more effectively.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up